LegoChem Biosciences Inc

LigaChem Biosciences Inc. is a clinical-stage biopharmaceutical company that discovers and develops medicines for unmet medical needs. It researches and develops products in therapeutic areas such as antibiotics, anti-fibrotics, immuno-oncology, and oncology, as well as antibody-drug conjugate (ADC) platform technology and small molecule drugs. The company also sells medical devices and supplies, and has a research collaboration and license agreement with AMGEN for the development and commercialization of ADCs. Formerly known as LegoChem Biosciences, Inc., it changed its name to LigaChem Biosciences Inc. in April 2024, was founded in 2006, and is headquartered in Daejeon, South Korea.